Skip to content
Evigrade
CriticalSSRI×Antifibrotic agents

Updated · Methodology

Mechanism

The liver metabolises 70–80% of pirfenidone through CYP1A2, with smaller contributions from CYP2C9, CYP2C19, CYP2D6 and CYP2E1 (pirfenidone summary of product characteristics, SmPC, European Medicines Agency, EMA). Fluvoxamine strongly inhibits CYP1A2 and CYP2C19 and, to a lesser extent, CYP2C9, CYP2D6 and CYP3A4 (fluvoxamine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), so it blocks several pirfenidone pathways at once (pirfenidone SmPC, EMA). In a study, fluvoxamine increased pirfenidone exposure fourfold in non-smokers (pirfenidone SmPC, EMA) and about sevenfold in smokers (pirfenidone label, US Food and Drug Administration, FDA). Higher exposure may change the adverse reaction profile of pirfenidone (pirfenidone FDA label).

Symptoms

The combination has no symptoms of its own: expect the adverse reactions of pirfenidone itself, such as nausea, diarrhoea, indigestion, vomiting, dizziness and fatigue (pirfenidone summary of product characteristics, SmPC, European Medicines Agency, EMA; pirfenidone label, US Food and Drug Administration, FDA). Photosensitivity reactions with a rash on sun-exposed skin may occur, and severe skin reactions are rarer (pirfenidone SmPC, EMA). Liver injury shows as a rise in alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Drug-induced liver injury causes fatigue, loss of appetite, discomfort under the right ribs, dark urine or jaundice (pirfenidone SmPC, EMA).

Management

The combination is contraindicated. Fluvoxamine is on the pirfenidone contraindication list: stop it before starting pirfenidone and do not use it at any time during pirfenidone treatment (pirfenidone summary of product characteristics, SmPC, European Medicines Agency, EMA). Do not stop fluvoxamine abruptly. Taper the dose over at least one to two weeks (fluvoxamine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label does not recommend the combination. If fluvoxamine is the only drug of choice, the US label reduces pirfenidone to 267 mg three times a day (801 mg a day). Monitor for adverse reactions and stop pirfenidone if needed (pirfenidone label, US Food and Drug Administration, FDA). The SmPC for Spain and the EU gives no such option. Advise patients starting pirfenidone to stop strong CYP1A2 inhibitors, not to smoke before or during treatment and to avoid grapefruit juice (pirfenidone SmPC, EMA). Check alanine aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin before starting pirfenidone, monthly for the first 6 months and every 3 months thereafter (pirfenidone SmPC, EMA). If pirfenidone and fluvoxamine have nevertheless been taken together, monitor for pirfenidone adverse reactions. If ALT or AST rises above 3 but below 5 times the upper limit of normal, without symptoms or raised bilirubin, look for other causes and reduce or interrupt pirfenidone if indicated. Stop pirfenidone permanently if the same rise comes with raised bilirubin or signs of liver injury, or if ALT or AST exceeds 5 times the upper limit of normal (pirfenidone SmPC, EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Fluvoxamine